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S U M M A R Y
Background: Untreated Chlamydia trachomatis infections in women can result in disease sequelae such as
salpingitis and pelvic inﬂammatory disease (PID), ultimately culminating in tubal occlusion and
infertility. Whilst nucleic acid ampliﬁcation tests can effectively diagnose uncomplicated lower genital
tract (LGT) infections, they are not suitable for diagnosing upper genital tract (UGT) pathological
sequelae. As a consequence, this study aimed to identify serological markers that can, with a high degree
of sensitivity and speciﬁcity, discriminate between LGT infections and UGT pathology.
Methods: Plasma was collected from 73 women with a history of LGT infection, UGT pathology due to C.
trachomatis, or no serological evidence of C. trachomatis infection. Western blotting was used to analyze
antibody reactivity against extracted chlamydial proteins. Sensitivity and speciﬁcity of differential
markers were also calculated.
Results: Four antigens (CT157, CT423, CT727 and CT396) were identiﬁed and found to be capable of
discriminating between the infection and disease sequelae state. Sensitivity and speciﬁcity calculations
showed that our assay for diagnosing LGT infection had a sensitivity of 75% and speciﬁcity of 76%, whilst
the assay for identifying UGT pathology demonstrated 80% sensitivity and 86% speciﬁcity.
Conclusions: The use of these assays could potentially facilitate earlier diagnoses in women suffering
UGT pathology due to C. trachomatis.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Chlamydia trachomatis is the most common sexually transmit-
ted bacterial pathogen and has the ability to exist in acute or
persistent states of infection. An untreated C. trachomatis infection
can result in disease sequelae such as salpingitis and pelvic
inﬂammatory disease (PID), and ultimately lead to tubal occlusion
and infertility.1,2 The asymptomatic nature of chlamydial infection
makes diagnosis difﬁcult, particularly in differentiating between
uncomplicated lower genital tract (LGT) infection and upper
genital tract (UGT) pathology. Current diagnostic tests for C.
trachomatis have variable performance capabilities with respect to
sensitivity, speciﬁcity, and disease/infection stages. The use of PCR
as a diagnostic tool is limited, as specimen collection is routinely
sampled from the LGT, hence infections in the fallopian tube or
UGT where inﬂammatory damage is most signiﬁcant, can escape
detection. Furthermore, PCR cannot determine whether UGT
pathology may have occurred. Serological assays aim to discrimi-* Corresponding author. Tel.: +61 7 3138 1900; fax: +61 7 3138 1524.
E-mail address: t.collet@qut.edu.au (T. Collet).
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doi:10.1016/j.ijid.2010.12.005nate the various disease stages of C. trachomatis infection through
identiﬁcation of key antigens, however their efﬁcacy is impeded
due to cross-reactivity between chlamydial species,3 and the
subsequent antibody response against the target antigen is not
restricted to patients with a speciﬁc stage of infection or
pathology.4 Consequently, several enzyme-linked immunosorbent
assays (ELISAs) have been developed that incorporate recombinant
C. trachomatis antigens to improve species speciﬁcity. The
Labsystems major outer membrane protein (MOMP) and Medac
lipopolysaccharide (LPS) tests have the ability to diagnose C.
trachomatis infection but lack the ability to identify the infection or
disease status, i.e., LGT infection or UGT pathology. Furthermore,
the Medac LPS assay has been reported to have low sensitivity and
high cross-reactivity between chlamydial species.5
Several studies have demonstrated a correlation between
antibody responses to chlamydial heat shock protein 60 (cHSP60)
and pathologic sequelae in women,6–8 including a signiﬁcant
association between the presence of antibodies to cHSP60 and
PID.8–10 An association of cHSP60 antibodies and tubal factor
infertility has also been reported.11–13 These observations have led
to the development of a commercial ELISA screening test based on
cHSP60 (Medac, Hamburg, Germany). Studies evaluating theses. Published by Elsevier Ltd. All rights reserved.
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demonstrated conﬂicting results, and thus the ability of the
cHSP60-based assay to distinguish various C. trachomatis disease
stages may be limited.4,14
Given the inability of current assays to reliably differentiate
between uncomplicated LGT infection and UGT pathology, we
undertook a serological approach to investigate novel C. tracho-
matis antigens that conferred increased power of discriminating
between these disease states. Samples obtained from seven patient
groups with various histories of chlamydial infection (LGT recent,
previous or recurrent infection, and those with UGT pathology/
disease sequelae with evidence of chlamydial involvement), were
screened using standard Western blotting techniques, to identify
differential reactive antigens. Four novel antigens showed
differential antibody responses between the C. trachomatis-
infected patient groups and could potentially be used to
discriminate uncomplicated LGT infection and UGT pathology
due to C. trachomatis.
2. Materials and methods
2.1. Sample collection and patient groups analyzed
Between 1998 and 2002, whole blood was collected in heparin
coated vials by peripheral venipuncture. Samples were centrifuged
(15 min, 3000 rpm, 4 8C) and the plasmawas retained and stored at
80 8C. Informed consent was obtained from all participants and
the study was approved by the human ethics committees of the
Queensland University of Technology, the Wesley Hospital, the
Prince Charles Hospital, and the Family Planning Clinic, Brisbane,
Queensland, Australia.Table 1
Clinical history and symptomology of Chlamydia trachomatis-infected patients in group
Patient group Patient ID C
Group I 13578 A
4081 A
13817 A
8015 A
13785 S
2361176 A
1996360 A
2248900 A
200612 A
Group II 1580 S
10622 D
339 A
14697 S
10306 T
18456 D
13619 C
10553 S
11036 A
17069 S
11796 V
Group III 4020 D
13108 D
9908 D
200611 A
Group IV 11011 P
13114 P
113 S
12581 H
IVF012 R
IVF013 S
IVF017 H
IVF029 H
IVF031 A
IVF032 H
PID, pelvic inﬂammatory disease.A total of 73 patients were analyzed as part of this study.
Individuals were assigned to one of seven groups according to the
following criteria: (a) group I: females diagnosed by PCRwith ﬁrst-
time C. trachomatis infection estimated to have been acquired
within the preceding 4 months (based on sexual history) (n = 9)
(Table 1); (b) group II: females who had been diagnosed by PCR
with ﬁrst-time C. trachomatis infection more than 12 months
previously (n = 11) (Table 1); (c) group III: females with a
documented history of two or more C. trachomatis infections,
with themost recent diagnosed by PCR and estimated to have been
acquiredwithin the preceding 4months (n = 4) (Table 1); (d) group
IV: females with presumptively diagnosed PID based on clinical
signs or documented history of clinical signs, a previous recorded
diagnosis of genital C. trachomatis infection or serological evidence
of C. trachomatis infection (n = 10) (Table 1); (e) group V: females
diagnosed with infertility following clinical investigations, but
laparoscopically showing no evidence of tubal occlusion due to
previous infection, with no previous documented history of PID
and negative C. trachomatis serology (n = 18); (f) group VI: adult
females with no serological evidence for C. trachomatis infection
(n = 13); and (g) group VII: females aged less than 16 years with no
serological evidence for C. trachomatis infection (n = 8).
Groups I–IV patient samples were obtained from women
attending either the Brisbane Sexual Health Clinic for ﬁrst-time
diagnosis or follow-up management of C. trachomatis infections
diagnosed by urine or swab-based PCR (see below), or from the
Family Planning Queensland Clinic (Brisbane, Australia). Groups IV
and V samples were obtained from women presenting to the
Wesley Hospital Department of Reproductive Medicine (Brisbane,
Australia) for laparoscopic and falloposcopic investigation of
infertility with diagnosis based on visual ﬁndings. Group VI
samples were collected from patients attending the Brisbane Reds I–IV at the time of blood collection
linical history and symptomology
symptomatic
symptomatic, hormone replacement therapy
symptomatic contact, mild cervix discharge
symptomatic contact
ymptomatic
symptomatic
symptomatic
symptomatic
symptomatic
ymptomatic, oral contraceptive pill
ysuria, abdominal pain, oral contraceptive pill
symptomatic, current thrush, oral contraceptive pill
ymptomatic, Depo Provera
hrush, Depo Provera
iagnosed with C. trachomatis 10 years previously
urrent bacterial vaginosis, discharge, history of herpes simplex virus
ymptomatic, oral contraceptive pill
bdominal pain
evere abdominal pain
aginal discharge, oral contraceptive pill
iagnosed 11 years prior, re-exposed 5 days ago, abdominal pain 1 year ago
iagnosed 1/1999 and 1/2000, symptomatic, herpes simplex virus
iagnosed 10/1997 and 7/1999, symptomatic
symptomatic, multiple infections
ast history C. trachomatis, PID on several occasions, currently pregnant
ID at 18 years of age
ymptomatic, repeated C. trachomatis infections over 3 years, presumptive PID
istory of PID for last 12 months, symptomatic for 1 year, oral contraceptive pill
ight tubal damage, history of miscarriage
evere bilateral tubal damage, C. trachomatis in fallopian tube
istory of PID
istory of PID, normal tubes
dhesions and bilateral tubal scarring
istory of PID, severe bilateral damage and adhesions
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blood specimens obtained from female children andmaintained at
the Queensland Medical Laboratory (Brisbane, Australia).
2.2. Analysis of chlamydial infection
Patient samples were assayed for C. trachomatis IgG using a
commercial enzyme immunoassay (EIA; Labsystems Chlamydia
trachomatis IgG EIA) with a 1/10 dilution, as per themanufacturer’s
instructions. Chlamydia pneumoniae serology was determined
using a commercial microimmunoﬂuorescence (MIF) assay (Focus
Diagnostics (USA) Chlamydia MIF IgG) according to the manu-
facturer’s instructions. Serology for anti-cHSP60 antibodies was
performed using the Medac cHSP60-IgG-ELISA (Medac, Hamburg,
Germany) commercial assay according to the manufacturer’s
instructions. Samples collected at the Brisbane Sexual Health Clinic
were also screened for Chlamydia infection by PCR. First catch
urine samples and genital swabs were assayed by Amplicor PCR
(Roche Diagnostics) testing according to the manufacturer’s
instructions.
2.3. C. trachomatis cell culture
HEp-2 cells were cultured in Dulbecco’s modied Eagle’s
medium (DMEM) supplemented with 5% heat-inactivated fetal
calf serum and 0.002% gentamicin under 5% CO2 and infected with
C. trachomatis L2 strain to achieve greater than 90% conﬂuency. At
30 h post-infection, cultures were extracted in 3 ml Laemmli
sample buffer15 and stored at 20 8C until required. In addition to
the infected culture (I), HEp-2 only cells (UI) were maintained and
extracted identically.
2.4. Identiﬁcation of reactive C. trachomatis proteins in patient
samples
Patient plasma samples were compared using equivalent
amounts of extracted Chlamydia/host cell proteins from the
uninfected (UI) and infected (I) HEp-2 cells. Brieﬂy, 10 mg of
extracts were separated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred to Hybond C Extra
nitrocellulose membranes (Amersham Biosciences). After blocking
with 5% skim milk powder in phosphate-buffered saline (PBS)
containing 0.1% Tween 20 (SM-PBS-T), patient plasma samples,
diluted 1:1000 in SM-PBS-T, were incubated with the membranes
at room temperature for 1 h, followed by horseradish peroxidase
conjugated rabbit anti-human IgG (Roche). Membranes were
washed then developed using chemiluminescence (Amersham
Biosciences ECL Plus Detection Kit). The presence of bands in the
infected (I) extracts that were not present in control uninfected
(UI) extracts were recorded and used to create the differential
diagnostic evaluations.Table 2
Summary of serology and infection status for all patient groups
Patient group Serological status HSP60 (
(%)
C. trachomatis
IgG (EIA) (%)
C. pneumoniae
IgG (MIF) (%)
I (n=9) 56 44 0
II (n=11) 45 55 27
III (n=4) 100 25 25
IV (n=10) 90 50 20
V (n=18) 0 44 5
VI (n=13) 0 31 8
VII (n=8) 0 25 13
HSP60, heat shock protein 60; EIA, enzyme immunoassay; MIF, microimmunoﬂuoresce
a Time lapsed since acquisition and diagnosis of C. trachomatis infection at time of b2.5. Immunoprecipitation with Chlamydia-speciﬁc antibodies
HEp-2 cell monolayers infected with C. trachomatis L2 for 24 h
were washed in cold PBS, trypsinized, lysed with 1% Triton X-100,
and clariﬁed by centrifugation at 12 000 rpm for 10 min at 4 8C.
One milliliter of supernatant was mixed with 20 ml patient sample
and incubated at 4 8C for 4 h. The lysate/antibody mix was next
mixed with 200 ml buffered protein G/micro-bead suspension
(Amersham Biosciences), incubated for 2 h at 4 8C, and pelleted by
centrifugation (6000 rpm for 40 s). After washing thoroughly in
50 mMTris pH 7.6 (150 mMNaCl, 0.1% NP40, 0.03% SDS), the pellet
was suspended in Laemmli sample buffer15 in a ﬁnal volume of
approximately 100ml. The sample was heated at 95 8C for 10 min
and stored at 20 8C. Bound proteins were separated and
transferred as described for Western blotting, except that an
Immobilon-P polyvinylidene ﬂuoride (PVDF) (Amersham Bios-
ciences) membrane was used. A segment of the membrane was
reserved for Western blotting, whilst the remaining membrane
was stained with Coomassie blue and washed in 90% methanol.
Western blotting was performed on the membrane segment as
described above. The antigenic targets were identiﬁed by aligning
Coomassie-stained membrane and Western blotted membrane
sections. The differential targets were excised from the membrane
and sequenced as below.
2.6. N-Terminal sequence analysis
Protein samples attached to PVDFmembrane were subjected to
Edman degradation (Australian Proteome Analysis Facility (APAF),
Macquarie University, Sydney) and sequences analyzed using NCBI
BLAST, ExPASy, and The Institute for Genomic Research (TIGR)
databases.
2.7. Antigenic target identiﬁcation and veriﬁcation via mass
spectrometry
Extracted chlamydial protein (infected culture (I)) was separated
onNU-PAGE4%–12%Bis–Tris, 1-well SDS-PAGEgels (Invitrogen) and
a small slice of gel containinga sectionofproteinwas transferred toa
Hybond C Extra nitrocellulose membrane (Amersham Biosciences)
and reserved for standard Western blotting using a single, strong-
reacting patient plasma sample. The remaining gel was Coomassie-
stained and aligned with the Western blot to identify antigenic
targets. Each target antigenwas excised from the Coomassie gel. Gel
sectionswere cut into small pieces and placed into pre-washed (50%
acetonitrile (ACN)/0.1% triﬂuoroacetic acid (TFA)) Eppendorf tubes.
Each gel piece was washed twice with 200ml of 200 mMNH4HCO3/
50% ACN at 37 8C for 45min and dried (Speedivac, Savant) on low
heat for 1 h. Samples were taken up in 25mM NH4HCO3, reduced
with 20 mM dithiothreitol (DTT) for 1 h at 65 8C, and then alkylated
with50 mMiodoacetamide for40minat37 8C.GelpiecesweredriedMedac ELISA) C. trachomatis infection,
median months (range)a
Infection number,
median (range)
1 (1) 0 (0)
50 (12–156) 1 (1)
1 (1) 3 (2–4)
13 (12–14) >2 (Unknown)
N/A N/A
N/A N/A
N/A N/A
nce assay; N/A, not applicable.
lood collection.
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trypsin, and incubated at room temperature for 1 h, followed by the
additionof twovolumesof25 mMNH4HCO3/50%ACNandincubated
at 37 8C for 18 h. Peptides recovered in the supernatant were mixed
with a 0.1% TFA wash of the pellet and subjected to mass
spectrometry (MS) analysis, with results examined using Mascot
software (Matrix Science).
2.8. Species and serovar speciﬁcity
To determine the species and serovar speciﬁcity of the
identiﬁed antigenic targets, C. trachomatis serovars L2, D, K andFigure 1. Typical Western blots of uninfected (UI) and infected (I) whole-cell extract
differential chlamydial antigenic bands designated A, B, C, and D. Exposure time afterC. pneumoniaewere cultured in HEp-2 cells and proteins extracted
as previously described. Plasma samples from patient groups I, II,
and IV were screened using 12.5% SDS-PAGE gels and Western
blotted against the four chlamydial protein extracts. Protein
alignments of the target antigens were performed using NCBI
BLAST, ExPASy, TIGR (http://www.tigr.org) and Sanger Institute C.
trachomatis L2 proteomic databases.
2.9. Diagnostic potential of antigenic targets
The results obtained from the four identiﬁed target antigens
were combined to evaluate their predictive potential for diagnos-s probed with samples from seven patient groups. Circled are the four identiﬁed
detection was 45 s.
Table 3
The percentage prevalence and estimatedmolecular weights of differential bands A, B, C, and D, including Chlamydia trachomatis EIA and Chlamydia pneumoniaeMIF serology
for each patient group
Patient group Differential bands (%) C. trachomatis, EIA (%) C. pneumoniae, MIF (%)
A B C D
Estimated band size (kDa) >113 72.4 44.6 13.5
I (n=9) 56 56 56 89 56 44
II (n=11) 45 27 45 45 45 55
III (n=4) 75 75 100 75 100 25
IV (n=10) 10 80 80 100 90 50
V (n=18) 6 11 17 28 0 44
VI (n=13) 0 8 0 54 0 31
VII (n=8) 0 0 0 0 0 25
EIA, enzyme immunoassay; MIF, microimmunoﬂuorescence assay.
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were combined to assess the prospect of diagnosing an uncompli-
cated LGT infection, whilst group IV was used to determine the
potential of an assay to detect UGT pathology. Groups V, VI, and VII
served as negative controls. Sensitivity, speciﬁcity, positive
predictive value (PPV), negative predictive value (NPV), and Chi-
square value (2002 Diagnostic Effectiveness Program, http://
www.quantitativeskills.com/sisa/statistics/diagnos.htm)were cal-
culated for each individual test format.
3. Results
3.1. Immunoreactivity patterns in females with C. trachomatis genital
infections
Table 2 summarizes the serology and infection status for all
patient groups. Figure 1 shows typical Western blot proﬁles
when plasma samples from each female group were used to
probe uninfected (UI) and C. trachomatis-infected (I) cell
preparations. Four bands, A (>113 kDa), B (72.4 kDa), C (44.6
kDa), and D (13.5 kDa), were differential between the patient
groups (Table 3). Of the four bands, the most commonly reactive
were C (65%) and D (76%). Band A was present in 10% of patient
samples in group IV (n = 10), compared to 56%, 45%, and 75% of
samples in groups I (n = 9), II (n = 11), and III (n = 4),
respectively. Of the 39 negative control patients tested, only
one (group V) reacted with this antigen. Band B was reactive in
75% of group III and 80% of group IV samples. Only 8% of the
negative controls reacted to band B. Group IV samples that were
reactive to band B also reacted with band C. Of the negative
control group V samples, 17% reacted to band C. All group IV
samples were reactive to band D. In addition, 89%, 45%, and 75%
of samples in groups I, II, and III, respectively, showed antibody
reactivity to band D. Antibody levels to C. pneumoniae and C.
trachomatis for all groups were determined by MIF and EIA,
respectively, prior to Western blot analysis. The overall
percentages of antibodies to C. pneumoniae ranged from 25%
to 55% in adults. MIF testing showed that 25% of patient samplesTable 4
Identiﬁcation of bands A, B, and C by N-terminal sequencing or mass spectrometry. Mo
where obtained, are indicated for each of the two potential candidates detected for ea
Band Gene Function
Band A CT147 Hypothetical proteina
CT314 DNA-directed RNA polymerase
Band B CT727 Metal transport P-type ATPase
CT396 Heat shock protein 70a
Band C CT157 Phospholipase D endonuclease
CT423 Cystathionine beta synthase d
a Mass spectrometry.
b N-Terminal sequencing.from the control group comprising children (group VII) were
positive for C. pneumoniae antibodies.
3.2. Identiﬁcation and veriﬁcation of chlamydial antigenic targets
N-Terminal sequencing yielded ﬁve to seven identiﬁable amino
acids for each of the three bands (A, B, and C) (Table 4). NCBI BLAST
searches showed band C to have 7/7 matches to CT157
(phospholipase D endonuclease) and 5/7 matches to the CT423
(cystathionine beta synthase (CBS)) domain. Band B showed the
ﬁrst ﬁve residues (DILMT) matched C. trachomatis protein CT727
(metal transport P-type ATPase).
Band A could not be identiﬁed by N-terminal sequencing as the
protein was not successfully precipitated from the C. trachomatis
host-cell lysate. However, MS analysis of the band A sample
identiﬁed two possible candidate proteins: CT147 (conserved
hypothetical protein; 162.1 kDa) and CT314 (DNA-directed RNA
polymerase beta chain; 154.9 kDa) (Table 4). MS analysis
suggested a match of band B to CT396 (HSP70; 70.8 kDa). Band
D could not be identiﬁed by either N-terminal sequencing or MS
due to the limited amount of isolated protein.
The amino acid sequences obtained for CT157, CT423, and
CT727 are internal to the protein. Original culture preparations of
cells infected with C. trachomatis used trypsin to detach infected
host cells, and thus the trypsin treatment may have cleaved the N-
terminal region from each of the three target antigens. To conﬁrm
this possibility, all three protein sequences were analyzed using
Peptide Cutter P (ExPASy) to determine potential trypsin cleavage
sites. Potential cleavage sites for CT423 matched the results
obtained by N-terminal sequencing. In contrast, the potential
cleavage sites predicted for CT157 and CT727 were located several
amino acids N-terminal of the ﬁrst residue detected by the N-
terminal sequencing analysis.
3.3. Species and serovar speciﬁcity of target antigens
Species and serovar speciﬁcity of the four antigenic targets
(bands A, B, C, and D) was determined by probing C. trachomatis L2,lecular weights (MW), predicted gene function, and N-terminal sequence residues
ch band
MW (kDa) N-Terminal sequence
162.1 None
a 154.9 None
b 70.5 DILMT
70.8 None
b 45.3 SPHTSQN
omainb 41.6 DPHTSQ
Figure 2. Typical Western blots showing species and serovar speciﬁcity of the four antigenic bands in patient groups I, II, and IV. The positions of the individual bands are
designated by arrows in patient groups I (a–c), II (d, e), and IV (f, g). Individual results of serology for Chlamydia trachomatis and Chlamydia pneumoniae are shown for each
patient along with identiﬁcation numbers (lane 1 = uninfected HEp-2 cells; lane 2 = HEp-2 cells infected with C. trachomatis L2; lane 3 = HEp-2 cells infected with C.
trachomatis D; lane 4 = HEp-2 cells infected with C. trachomatis K; lane 5 = HEp-2 cells infected with C. pneumoniae. Exposure time after detection was 45 s).
Table 5
Serovar and species speciﬁcity and serology for patient samples from groups I, II, and IV, probed against Chlamydia trachomatis serovars L2, D, and K, and Chlamydia
pneumoniae
Patient group Patient ID Serology (IgG) L2 D K C. pneumoniae
I 8015 Ct-neg; Cpn-pos A/D None None D
13817 Ct-pos; Cpn-pos A/B/C/D A/B A/B A/B/C
13785 Ct-pos; Cpn-neg A/C/D A A A/C
13578 Ct-pos; Cpn-neg D None None None
2248900 Ct-neg; Cpn-neg B/D B B B/D
II 10622 Ct-pos; Cpn-neg A/B/C B B A/B/C
14697 Ct-pos; Cpn-pos C/D None None C/D
10306 Ct-pos; Cpn-neg A None None None
18456 Ct-pos; Cpn-pos A/B/C/D B/D B/D D
10553 Ct-neg; Cpn-neg A/B/D None None D
IV 11011 Ct-pos; Cpn-neg B/C/D C C B/C/D
12581 Ct-pos; Cpn-neg B/C/D C B/C C/D
113 Ct-pos; Cpn-pos A/B/C/D A/B A/B/C/D A/B
IVF017 Ct-pos; Cpn-neg B/C/D B B/D None
IVF032 Ct-pos; Cpn-neg B/C/D B/C B/C/D B/C/D
Ct, Chlamydia trachomatis; Cpn, Chlamydia pneumoniae.
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Table 6
Assessment of the diagnostic potential of different panel formats for the diagnosis of acute and chronic chlamydial infection. Panel format 3 (A or B or C) proved to be the
superior format for the diagnosis of uncomplicated lower genital tract Chlamydia trachomatis infection. The B+C format demonstrated the greatest efﬁcacy for diagnosing
upper genital tract pathological sequelae
Infection stage Panel format Sensitivity % Speciﬁcity % PPV % 95% CI SE NPV % 95% CI SE Chi-square
Uncomplicated LGT 1. A+B or C 33 96 80 0.552 0.126 75 0.476 0.137 11.6
2. A+C or B 42 96 83 0.622 0.107 77 0.533 0.121 16.5
3. A or B or C 75 76 60 0.423 0.089 86 0.736 0.063 16.9
4. A or B or C or D 79 55 46 0.311 0.077 84 0.733 0.056 7.6
5. B or C or D 75 55 45 0.296 0.078 82 0.699 0.060 5.8
UGT pathology 6. B+C 80 86 47 0.233 0.121 96 0.877 0.045 20.9
LGT, lower genital tract; UGT, upper genital tract; +, both antigens must be positive; PPV, positive predictive value; CI, conﬁdence interval; SE, standard error; NPV, negative
predictive value.
T. Collet et al. / International Journal of Infectious Diseases 15 (2011) e257–e266 e263D, and K, and C. pneumoniae-cell extracts with plasma samples
from groups I, II, and IV (Figure 2). Group III was not included in
this comparative study as all the samples from each patient were
used during the initial Western blot screen. In general, none of the
four target antigens were found to be serovar- or species-speciﬁc
(Table 5). Moreover, patient samples serologically identiﬁed as
positive for both C. trachomatis and C. pneumoniae appeared to be
more highly reactive across the chlamydial serovars and species
tested regardless of which group the samples were from.
In each patient group, samples positive for C. trachomatis and
negative for C. pneumoniae demonstrated similar antibody
reactivity to the antigenic targets in comparison to the original
C. trachomatis L2 extract and the D, K, and C. pneumoniae protein
preparations. Bands A and B were the least reactive when samples
from each of the three groups were probed against C. pneumoniae.Figure 3. Comparison of female antibody responses to bands A, B, C, and D for Chlamydi
temporal scale, the even spacing of the stages is purely arbitrary, not necessarily reﬂecGroup I and group II patients more commonly elicited an antibody
response to bands A and B. In contrast, patients with UGT
pathology (group IV) seem to produce antibodies more frequently
against bands B and C.
All four antigens showed 95% sequence conservation between
homologous proteins of C. trachomatis serovars L2 and D, and C.
pneumoniae. In contrast, the level of sequence similarity amongst
the C. pneumoniae proteins and their homologues in C. trachomatis
varied from 9% to 87%. CT157 showed 94% homology between C.
trachomatis serovars L2 and D, whilst the C. pneumoniae protein
shared only 9% sequence identity to the C. trachomatis protein. The
C. pneumoniae CT423 homologue showed 44% sequence identity to
the C. trachomatis protein, which as a group, shared 95% sequence
homology between serovars. A high level of sequence conservation
was evident for C. trachomatis CT727 (99%) and CT396 (100%) L2a trachomatis-infected patient groups I – IV. Although the x-axis is interpreted as a
ting a ‘to-scale’ timeline.
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showed 72% and 87% sequence identity for CT727 and CT396,
respectively.
3.4. Diagnostic potential of the four newly identiﬁed bands
To discriminate between uncomplicated LGT infection and
UGT pathology, the results obtained from the four identiﬁed
antigens were combined into various panels and their predictive
potential evaluated. Of the 28 possible combinations, only those
displaying the highest overall diagnostic potential are shown in
Table 6. Antibody response to panel format 3 (antigens A or B or
C) demonstrated the greatest sensitivity (75%) and speciﬁcity
(76%) compared to other potential formats for the prediction of
LGT infections. In contrast, other panel formats such as panel 1
(A + B or C) and panel 2 (A + C or B) showed signiﬁcantly lower
sensitivities of 33% and 42%, respectively, but demonstrated
higher speciﬁcity (96%). The panel 4 format (A or B or C or D)
displayed the greatest sensitivity of 79%; however the addition
of antigen D when compared to the A or B or C format decreased
speciﬁcity by 21%. The removal of antigen A from the A or B or C
or D panel format (i.e., to B or C or D), did not improve diagnostic
discrimination; in fact, sensitivity and positive and negative
predictive values were slightly reduced. Only one combination
of antigens was selected to be assessed for its predictive value in
the diagnosis of UGT pathology, as the initial Western blot
screen of samples from group IV demonstrated 8/10 samples
reacted to both B and C antigens. As a consequence, the B + C
panel format was evaluated and subsequently demonstrated
80% sensitivity and 86% speciﬁcity for the potential diagnosis of
UGT pathology.
3.5. Antibody response of identiﬁed antigens during stages of C.
trachomatis infection
The antibody responses of bands A, B, C, and D in females with
histories of uncomplicated C. trachomatis infection and pathologi-
cal sequelae were compared (Figure 3). In general, antibody
proﬁles of the antigens showed a much stronger response in group
III patients compared with the other groups. Furthermore, each
target antigen demonstrated a decrease in the antibody response
after 12months post-infection (patient group II). Antigens A, B, and
C exhibited an identical antibody response (56%) in group I
patients, whilst antibody production to antigen D was markedly
increased (89%).
The antibody response proﬁle of band A suggests a moderate
(56%) acute antibody response (patient group I), a slight
decrease (45%) over time post-infection (group II patients), a
rise (75%) in those who are re-infected (patient group III), and a
sharp decline in those with UGT pathology (patient group IV)
due to C. trachomatis infection. During primary infection (patient
group I), moderate levels (56%) of antibodies to band B are
produced and the post-infection phase (patient group II) shows
a decrease in antibody production. The antibody proﬁle of band
C in the acute (patient group I) and post-infection (patient group
II) stages virtually mimics that of bands A and B, however the
pathological sequelae due to C. trachomatis infection (patient
group IV) elicit a much stronger antibody response. Antibody
levels to band D in primary infection (patient group I) elicit a
much more vigorous response (89%) when compared to the
acute proﬁles of bands A, B, and C. The post-infection phase
(patient group II) shows a rapid drop of antibodies produced to
band D, whilst in patient groups III and IV, the generation of
antibodies increases from 75% to 100%, respectively, thus
surpassing the antibody response demonstrated by patients
with primary infection (group I).4. Discussion
This study aimed to identify one or more chlamydial antigens
that could be used to discriminate between uncomplicated LGT
infection and UGT pathology due to C. trachomatis. Four bands
were able to distinguish between LGT infection and UGT pathology
in affected women. Two possible candidates were identiﬁed for
each of bands A (CT147 and CT314), B (CT727 and CT396), and C
(CT157 and CT423).
Band A, reactive in 38% of C. trachomatis-infected samples, was
identiﬁed as two possible candidate proteins: CT147 (conserved
hypothetical protein; 162.1 kDa) and CT314 (DNA-directed RNA
polymerase beta chain; 154.9 kDa). Only CT147 has previously
been shown to elicit a humoral response as expected from the
protein’s localization to the inclusionmembrane of the elementary
body (EB).16 Of the C. trachomatis-infected samples, groups I and III
demonstrated the highest reactivity (56% and 75%, respectively) to
band A. The alternative band A candidate, CT314, functions as a
transcriptional regulator and would not be expected to be
presented to the host immune system at any stage during the
chlamydial developmental cycle or infection process. Therefore,
given the functional role of CT314, the probability of a humoral
response targeted against this protein is unlikely.
The two candidate proteins for band B are CT727 (P-type
ATPase) and CT396 (HSP70). P-type ATPases constitute a super-
family of cation transport enzymes that mediate transmembrane
exchange of all biologically signiﬁcant cations.17 In contrast, HSP70
is associated with outer membrane complexes of EBs and was
originally thought to play a role in either attachment or entry of the
EB into host cells.18,19 Although heat shock proteins are expressed
during times of stress, such as bacterial invasion, Raulston et al.20
showed that HSP70 is only exposed on the surface of puriﬁed EBs to
a minor degree. The functionality of CT396 suggests that HSP70
does indeed confer a humoral antibody response. This is supported
by comparative sequence analysis that showed CT396 is almost
totally conserved between C. trachomatis and C. pneumoniae and as
such, anti-CT396 antibodies would be expected to demonstrate
equal reactivity when probed against C. pneumoniae. However, the
latter was not the case in any of the 15 patient samples tested.
One of the candidate proteins for band C, CT157, contains two
phospholipase D (PLD) domains and is a member of the PLD
superfamily, which includes enzymes that have high catalytic
activity and are involved in phospholipid metabolism. PLDs, which
are known to hydrolyze phospholipids to phosphatidic acid, may
be essential for the formation of particular types of transport
vesicles or be strongly involved in signal transduction.21 CT423, the
second protein candidate for band C, contains three functional
domains (two CBS domains and one transporter-associated
domain) that are implicated in intracellular targeting and
trafﬁcking as well as protein–protein interactions.22 Neither of
these band C candidate proteins have previously been reported to
induce a humoral response in the host, yet antibody production to
one or both of these proteins was demonstrated in all but the
uninfected child controls (group VII). CT157 is the least conserved
(9%) of the band C candidate proteins, and antibody reactivity for
band C was shown to be greatly decreased against C. pneumoniae.
Sensitivity and speciﬁcity showed that bands B and C were not as
reactive to C. pneumoniae by comparisonwith C. trachomatis. Taken
together, these ﬁndings suggest that the true identities of bands B
and C are CT727 and CT157, respectively.
N-terminal sequencing of proteins isolated from bands B and C
revealed sequences contained internally within CT157, CT423, and
CT727. However, the sequence DPHTSQ, which identiﬁed the
protein CT423, was predicted to be cleaved by trypsin at the lysine
(K) residue directly preceding the ﬁrst amino acid of the identiﬁed
sequence. CT157 and CT727 were cleaved three and four amino
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Little is known about how CT157, CT423, and CT727 are
intracellularly processed and it is possible that the missing amino
acids were removed during maturation of the protein within the
cell. There is also a possibility that various host cell proteases may
have cleaved CT157, CT423, and CT727 post-translationally, thus
resulting in truncated proteins. An attempt was made to N-
terminal sequence the protein isolated from band A, however
Belland et al.16 showed that during immunoprecipitation, CT147 is
cleaved leaving a 90-kDa fragment. If the identity of the
immunoreactive band A is indeed the CT147 protein, then this
would account for the inability of the approach to identify this
protein, as the immunoreactive band present on the PVDF
membrane was excised at a molecular weight > 113 kDa.
Sensitivity and speciﬁcity of the identiﬁed antigens in various
combinations showed the A or B or C format (panel 3) to be the
most efﬁcacious for diagnosing uncomplicated LGT infection. The
addition of antigen D to the panel (A or B or C or D) was shown to
increase the sensitivity to 79%. However, given the overall
prevalence of antigen D in samples from C. trachomatis-infected
patients, the diagnostic potential of antigen D for speciﬁcally
identifying LGT infection is limited due to the high C. pneumoniae
cross-reactivity demonstrated within UGT patients. Moreover, this
suggests that antigen D could possibly be more useful as a marker
of general chlamydial infection rather than of a particular stage of
infection. With a sensitivity of 80% and speciﬁcity of 86%, UGT
pathology could potentially be diagnosed using the B + C format.
Nonetheless, a small number of women with histories of LGT
infection were also reactive to bands B + C. Therefore, future
applications of this assay format should only be used as an initial
screening tool supported by conﬁrmatory investigations of greater
speciﬁcity.
Only one other assay for the potential diagnosis of UGT or C.
trachomatis-induced sequelae is currently available, the Medac
HSP60 – an assay for the detection of anti-cHSP60 antibodies.
Higher anti-cHSP60 antibody responses in women with tubal
pathology have been demonstrated compared to women without
tubal pathology.14 However, Gazzard et al.4 showed a reduction of
cHSP60 reactivity in the PID/tubal damage group (20%) compared
to patients with uncomplicated infection (28%). In our study, anti-
cHSP60 antibodies were not detected in women infected less than
4 months (group I), contrary to expectations. Furthermore, the
number of patient samples fromeach C. trachomatis-infected group
in which anti-cHSP60 antibodies were detected was only 18%, i.e.,
3/38 for group II (post-infection) and 2/38 for groups III (multiply
infected) and IV (PID). The validity of the assay is further
challenged by the detection of anti-cHSP60 antibodies in a single
sample from each negative control group. Thus, the use of the
Medac HSP60 assay as an indicator of UGT pathology in our female
cohort provides a sensitivity of 18% and speciﬁcity of 87%, which is
signiﬁcantly lower than the sensitivity (80%) of our newly
developed B + C format.
This study has some limitations centered on the small sample
sizes for many of the patient cohorts; this prevented rigorous
statistical analysis. However, the results clearly point to a powerful
discriminator of LGT and UGT pathology. In addition, despite the
great care with which patients were allocated to particular sample
groups, the rigor for each of the deﬁned cohorts is uncertain given
the reliance upon self-reported sexual histories to determine time
of infection and previous infection status. Further, in deﬁning those
women in group IV, clinical diagnosis of PID in many cases was
derived without supporting laparoscopic evidence, and the link
with Chlamydia causation was circumstantial, being based on
previous PCR diagnosis or more tentative serological evidence.
Selection of chlamydial strains for determining species and serovar
speciﬁcity of the target antigens was limited to L2, D, and K, asexamination of other serovars was beyond the scope of this study.
Moreover, C. trachomatis L2 was chosen as it was the primary
serovar used for the duration of the study, whilst D and K strains
were selected as both have the potential to cause UGT pathology,
the focus of this research.
The ability to identify UGT pathology progressing from C.
trachomatis infection would be a signiﬁcant advance in the
management of chlamydial infection or disease. Early diagnosis
of pathology or the identiﬁcation of its potential onset would allow
for timely interventions that could prevent serious tubal damage.
Individuals with a history or risk of multiple chlamydial infections
could be monitored at each subsequent re-infection to identify the
likelihood of progression to sequelae. Furthermore, a reliable
serological test for C. trachomatis-induced UGT infections could be
used as a predictor of those women most likely to progress to
inﬂammatory damage, thereby allowing for more intensely
targeted preventative education to reduce risks of re-infection
in this subpopulation of women. Importantly, this study provides a
diagnostic basis for a potential discriminator of LGT infection and
UGT pathology.
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